| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BCTC is a selective and orally bioactive vanilloid receptor 1 (TRPV1 receptor) antagonist. Inhibits acid- and capsaicin-induced activation of rat TRPV1 receptors (IC50 are 6.0 and 35 nM respectively). BCTC significantly reduced the accompanying thermal and mechanical hyperalgesia (3 mg/kg and 10 mg/kg p.o., respectively). BCTC also reduced mechanical hyperalgesia and tactile allodynia 2 weeks after partial sciatic nerve injury (10 and 30 mg/kg p.o.). BCTC did not affect motor performance on the rotarod after administration of doses up to 50 mg/kg p.o.
| ln Vitro |
On DU145 cells, BCTC (20-100 μM; 72 h) exhibits very specific anti-tumor action [1]. By selectively controlling the expression levels of a handful of cell cycle regulatory proteins, BCTC (20-100 μM; 48 h) produces cell cycle arrest in the G0/G1 phase without inducing apoptosis (10 μM and 100 μM; 72 h). Demise [1]. Cell migration and invasion are inhibited by BCTC (10μM and 100μM; 48 h) [1]. Rat spinal cord TRPV1 function is effectively inhibited by BCTC (3-300 nM), which also reduces capsaicin (300 nM)-induced calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) (IC50=37.0 nM) and p-like substance immunoreactivity in rat spinal cord slices (SP-LI) (IC50=36.0 nM) [3].
|
|---|---|
| ln Vivo |
By targeting VR1, BCTC (1-30 mg/kg; oral administration; single dosage) has analgesic effects and can reduce neuropathic and inflammatory thermal allodynia as well as mechanical hyperalgesia in Sprague-Dawley rats[2]. In diabetic ob/ob mice, BCTC (10–100 mg/kg; oral dosing, twice daily for 4 weeks) can enhance insulin production and improve systemic glucose and lipid metabolism as well as insulin resistance [5].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: DU145 Tested Concentrations: 20 μM, 40 μM, 60 μM, 80 μM, 100 μM Incubation Duration: 48 h Experimental Results: Down-regulates p-Akt, while p-GSK-3β is up-regulated leaving their unphosphorylated form unchanged. Dramatically down-regulated Cyclin D1(20), the most relevant protein in the cell cycle, without affecting cyclin-B1. decreased the expression of CDK2 and CDK6, but without affecting the expression level of CDK4. Downregulates MMP2 and p-FAK levels. Cell Viability Assay[1] Cell Types: DU145, PNT1A Tested Concentrations: 20 μM, 40 μM, 60 μM, 80 μM, 100 μM Incubation Duration: 72 h Experimental Results: diminished the growth of DU145 cells in a concentration -dependent manner, with 12.03% and 50.69% growth inhibition at 10 µM and 100 µM, respectively, but had little effect on normal prostate PNT1A cells. |
| Animal Protocol |
Animal/Disease Models: Capsaicin-induced SD (Sprague-Dawley) rats model[2]
Doses: 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Route of Administration: po (oral gavage), Single dose. Before capsaicin treatment ( 30 μg; intraplantar injection; Single dose) Experimental Results: Inhibited capsaicin-mediated thermal hyperalgesia in a dose-dependent manner. Animal/Disease Models: Freund's complete adjuvant (FCA) SD (Sprague-Dawley) rats model[2] Doses: 1 mg/kg, 3 mg /kg, 10 mg/kg, 30 mg/kg Route of Administration: po (oral gavage), Single dose. After 100 % FAC treatment (50 μL; intraplantar injection; Single dose) Experimental Results: Dramatically decreased FAC-induced inflammation-related thermal pain and mechanical hyperalgesia, and extended the inhibitory effect of mechanical hyperalgesia to 6 h at high doses (10 mg/kg, 30 mg/kg). Animal/Disease Models: Partial sciatic nerve ligation SD (Sprague-Dawley) rats model[2] Doses: 1 mg/ kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Route of Administration: po (oral gavage), Single dose. After partial sciatic nerve ligation. Experimental Results: decreased post-operative ab |
| References |
[1]. Liu T, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11(1):182-188.
[2]. Pomonis JD, et al. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflamm [3]. Valenzano KJ, et al. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic pro |
| Additional Infomation |
1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- is a member of piperazines and a member of pyridines.
|
| Exact Mass |
372.171
|
|---|---|
| CAS # |
393514-24-4
|
| Related CAS # |
393514-24-4;
|
| PubChem CID |
9929425
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
561.6±50.0 °C at 760 mmHg
|
| Flash Point |
293.4±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.610
|
| LogP |
4.08
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N1CCN(C2=NC=CC=C2Cl)CC1)NC3=CC=C(C(C)(C)C)C=C3
|
| InChi Key |
ROGUAPYLUCHQGK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
|
| Chemical Name |
N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~134.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
